Vetoquinol SA
Gesloten
SectorGezondheidszorg
68.7 -0.43
Overzicht
Wijziging aandelenprijs
24u
Min
67.2
Max
68.9
Inkomsten | 7.2M 32M |
|---|---|
Verkoop | 10M 268M |
K/W Sectorgemiddelde | 14.069 49.712 |
Dividendrendement | 1.33 |
Winstmarge | 12.043 |
Werknemers | 2,422 |
EBITDA | 252M 301M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +59.65% upside |
Dividendrendement Sectorgemiddelde | 1.33% 2.36% |
|---|---|
Volgende Winsten | 11 sep 2026 |
Marktkapitalisatie | -127M 808M |
|---|---|
Vorige openingsprijs | 69.13 |
Vorige sluitingsprijs | 68.7 |
Nieuwssentiment
By Acuity
50%
50%
166 / 342 Rangschikking in Healthcare
Vetoquinol SA Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
